UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Molecular oncology, 2014-07, Vol.8 (5), p.874-883

2014

Volltextzugriff (PDF)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer

Molecular oncology, 2018-06, Vol.12 (6), p.925-935

2018

Volltextzugriff (PDF)

Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression

PloS one, 2018-01, Vol.13 (1), p.e0189887-e0189887

2018

Volltextzugriff (PDF)

Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women

PloS one, 2014-07, Vol.9 (7), p.e101950-e101950

2014

Volltextzugriff (PDF)

Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7483-7490

2005

Volltextzugriff (PDF)

Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis

Oncotarget, 2015-03, Vol.6 (8), p.5634-5649

2015

Volltextzugriff (PDF)

HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients

Journal of clinical oncology, 2010-02, Vol.28 (6), p.984-990

2010

Volltextzugriff (PDF)

Patients' experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy

Research involvement and engagement, 2019-11, Vol.5 (1), p.36-36, Article 36

2019

Volltextzugriff (PDF)

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Breast cancer (Tokyo, Japan), 2020-03, Vol.27 (2), p.266-276

2020

Volltextzugriff (PDF)

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (8), p.735-740

2018

Volltextzugriff (PDF)

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3376-3384

2001

Volltextzugriff (PDF)

Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice

Acta oncologica, 2024-05, Vol.63, p.277-287

2024

Volltextzugriff (PDF)

Aberrations of ERBB2 and TOP2A genes in breast cancer

Molecular oncology, 2010-04, Vol.4 (2), p.161-168

2010

Volltextzugriff (PDF)

Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

Acta oncologica, 2015-04, Vol.54 (4), p.530-537

2015

Volltextzugriff (PDF)

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

Acta oncologica, 2018-01, Vol.57 (1), p.135-140

2018

Volltextzugriff (PDF)

Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence

Scientific reports, 2017-03, Vol.7 (1), p.43813-43813, Article 43813

2017

Volltextzugriff (PDF)

Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

Acta oncologica, 2018-01, Vol.57 (1), p.31-37

2018

Volltextzugriff (PDF)

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

European journal of cancer (1990), 2014-05, Vol.50 (8), p.1412-1421

2014

Volltextzugriff (PDF)

Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter

Clinical cancer research, 2015-08, Vol.21 (15), p.3569-3569

2015

Volltextzugriff (PDF)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

ESMO open, 2016, Vol.1 (4), p.e000062-e000062, Article e000062

2016

Volltextzugriff (PDF)

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

Breast cancer research and treatment, 2015-12, Vol.154 (3), p.483-494

2015

Volltextzugriff (PDF)

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high‐risk, premenopausal breast cancer

Cancer, 2010-05, Vol.116 (9), p.2081-2089

2010

Volltextzugriff (PDF)

Correlation between circulating cell‐free PIK 3 CA tumor DNA levels and treatment response in patients with PIK 3 CA ‐mutated metastatic breast cancer

Molecular oncology, 2018-06, Vol.12 (6), p.925-935

2018

Volltextzugriff (PDF)

YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

Breast cancer research and treatment, 2008-11, Vol.112 (2), p.275-285

2008

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(100)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer

Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression

Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women

Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group

Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis

HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients

Patients' experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice

Aberrations of ERBB2 and TOP2A genes in breast cancer

Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence

Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high‐risk, premenopausal breast cancer

Correlation between circulating cell‐free PIK 3 CA tumor DNA levels and treatment response in patients with PIK 3 CA ‐mutated metastatic breast cancer

YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Suchergebnisse filtern